Vasoactive drugs for vasodilatory shock in ICU

Current Opinion in Critical Care

Volumn 15, Issue 5, 2009, Pages 398-402

  Holmesa, Cheryl L ^a   Walley, Keith R ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Corticosteroids; Dobutamine; Epinephrine; Metoprolol; Milrinone; Norepinephrine; Phenylephrine; Sepsis syndrome; Septic shock; Terlipressin; Vasopressin

Indexed keywords

ADRENALIN; CORTICOSTEROID; DOBUTAMINE; DOPAMINE; HYDROCORTISONE; HYPERTENSIVE FACTOR; METOPROLOL; MILRINONE; NORADRENALIN; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; TERLIPRESSIN; VASOPRESSIN;

CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPOTENSION; INSULIN TREATMENT; INTENSIVE CARE UNIT; LACTIC ACIDOSIS; LOW DRUG DOSE; REVIEW; SEPTIC SHOCK; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TREATMENT OUTCOME; VASODILATORY SHOCK;

CARDIOTONIC AGENTS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; INTENSIVE CARE UNITS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 70350104908     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32832e96ef     Document Type: Review

References (22)

1. Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med 2004;32:S455-S465.
2. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595.
3. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
4. Mullner M, Urbanek B, Havel C, et al. Vasopressors for shock. Cochrane Database Syst Rev 2004:CD003709.
5. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327. This review reports a consensus of opinion regarding the vasoactive management of septic shock, based on available evidence.
6. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887. Although low-dose vasopressin did not reduce mortality compared with norepinephrine among septic shock patients, vasopressin is well tolerated and may be beneficial in patients having less severe septic shock. This study also confirmed the deficiency of endogenous vasopressin levels in septic shock and that infusion of 0.03U/min restored serum vasopressin levels to an appropriate level for shock.
7. Myburgh JA, Higgins A, Jovanovska A, et al., CAT Study investigators. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008; 34:2226-2234. This randomized controlled trial found no difference in outcomes between epinephrine and norepinephrine in the treatment of septic shock.
8. Morelli A, Ertmer C, Rehberg S, et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care 2008; 12:R143. This study suggests that there are no differences in cardiopulmonary performance, global oxygen transport and regional hemodynamics between phenylephrine and norepinephrine in the hemodynamic support of septic shock.
9. Morelli A, Ertmer C, Lange M, et al. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth 2008; 100:494-503. This is the first randomized controlled trial showing that terlipressin bolus administration reduces norepinephrine requirements in septic shock patients; however, high doses of dobutamine are needed to reverse the terlipressin-linked cardiovascular effects.
10. Ertmer C, Rehberg S, Morelli A, Westphal M. Current place of vasopressin analogues in the treatment of septic shock. Curr Infect Dis Rep 2008;10:362-367. This review summarizes the effects of vasopressin and terlipressin in the treatment of septic shock and gives recommendations for the practical use of vasopressin analogues.
11. Westphal M, Rehberg S, Ertmer C, Andrea M. Terlipressin -more than just a prodrug of lysine vasopressin? Crit Care Med 2009; 37:1135-1136.
12. Vincent JL. Is the current management of severe sepsis and septic shock really evidence based? PLoS Med 2006; 3:e346.
13. Dopamine versus norepinephrine for the treatment of vasopressor dependent septic shock on world wide web URL. http://clinicaltrials.gov/ct2/show/ NCT00604019?term=NCT00604019&rank=1.
14. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124. Although corticosteroids did not decrease mortality of patients having septic shock, and cannot be recommended, hydrocortisone may have a role among patients who are vasopressor unresponsive.
15. Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009;37:811-818. This substudy of VASST found an interaction between vasopressin and corticosteroids. The combination of low-dose vasopressin and corticosteroids was associated with decreased mortality and organ dysfunction compared with norepinephrine and corticosteroids.
16. Annane D. Vasopressin plus corticosteroids: the shock duo! Crit Care Med 2009; 37:1126-1127.
17. Boyd JH, Mathur S, Wang Y, et al. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 2006; 72:384-393.
18. Court O, Kumar A, Parrillo JE. Clinical review: myocardial depression in sepsis and septic shock. Crit Care 2002; 6:500-508.
19. Boyd JH, Chau EH, Tokunanga C, et al. Fibrinogen decreases cardiomyocyte contractility through an ICAM-1-dependent mechanism. Crit Care 2008;12:R2.
20. Boyd JH, Kan B, Roberts H, et al. S100A8 and S100A9 mediate endotoxininduced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 2008; 102:1239-1246.
21. Vieillard-Baron A, Caille V, Charron C, et al. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 2008; 36:1701-1706. Global left ventricular hypokinesia is more frequent in septic shock than previously known and can be unmasked by norepinephrine treatment.
22. Schmittinger CA, Dunser MW, Haller M, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care 2008; 12:R99. Low doses of metoprolol in combination with phosphodiesterase inhibitors are feasible in patients with septic shock and cardiac depression but no overt heart failure. b-Blockers in the setting of septic cardiomyopathy may have a role.